-
Signature
-
Brett Sandercock, Chief Financial Officer
-
Issuer symbol
-
RMD
-
Transactions as of
-
08 May 2024
-
Transactions value $
-
-$1,528,130
-
Form type
-
4
-
Filing time
-
10 May 2024, 15:21:52 UTC
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
RMD |
ResMed Common Stock |
Options Exercise |
$1.22M |
+12K |
+12.9% |
$101.64 |
105K |
08 May 2024 |
Direct |
F1, F2 |
| transaction |
RMD |
ResMed Common Stock |
Sale |
-$2.75M |
-13K |
-12.37% |
$211.37 |
92.1K |
08 May 2024 |
Direct |
F1 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
RMD |
ResMed Common Stock Options |
Options Exercise |
$0 |
-12K |
-52.44% |
$0.00 |
10.9K |
08 May 2024 |
ResMed Common Stock |
12K |
$101.64 |
Direct |
F1, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: